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Abstract
Purpose There is an increasing interest in use of treosulfan
(TREO), a structural analogue of busulfan, as an agent in
conditioning regimens prior to hematopoietic stem cell trans-
plantation (HSCT), both in pediatric and adult populations.
The aim of this study was to develop a population pharmaco-
kinetic model and to establish limited sampling strategies
(LSSs) enabling accurate estimation of exposure to this drug.
Methods The study included 15 pediatric patients with malig-
nant and non-malignant diseases, undergoing conditioning
regimens prior to HSCT including TREO administered as a
1 h or 2 h infusion at daily doses of 10, 12, or 14 g/m2. A
population pharmacokinetic model was developed by means
of non-linear mixed-effect modeling approach in Monolix®
software. Multivariate regression analysis and Bayesian meth-
od were used to develop 2- and 3-point strategies for estima-
tion of exposure to TREO.
Results Pharmacokinetics of TREOwas best described with a
two-compartmental linear model with proportional residual
error. Following sampling schedules allowed accurate estima-
tion of exposure to TREO: 1 h and 6 h or 1 h, 2 h, and 6 h for a
TREO dose 12 g/m2 in a 1 h infusion, or at 2 h and 6 h or 2 h,
4 h, and 8 h for a TREO dose of 12 g/m2 and 14 g/m2 in a 2 h
infusion.
Conclusions A two-compartmental population pharmacoki-
netic model of TREO was developed and successfully used
to establish 2- and 3-point LSSs for accurate and precise esti-
mation of TREO AUC0→∞.
Keywords Hematopoietic stem cell transplantation . Area
under curve . Infusions, intravenous . Population
pharmacokinetics
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is a procedure aimed at reconstituting normal hemato-
poiesis in malignancies and non-malignant hematopoietic dis-
orders [1]. A conditioning regimen prior to HSCT is required.
It should demonstrate myeloablative and immunosuppressive
and, in case of malignant disorders, anti-malignancy proper-
ties to prevent graft rejection, graft versus host disease and
post-transplant relapse of malignancy. Commonly, the
myeloablative conditioning procedure consists of fractionated
total body irradiation or myeloablative dose of busulfan com-
bined with high-dose cytostatics, such as etoposide,
fludarabine, melphalan, thiotepa or cyclophosphamide [2].
Recent clinical studies indicate that also high-dose treosulfan
(TREO), which is a structural analogue of busulfan, demon-
strates significant myeloablative and immunosuppressive
properties as well as anti-malignant activity in case of hema-
tological malignancies and some solid tumors [3–5].
According to these studies, TREO has relatively mild toxicity
profile [5, 6].
TREO is a prodrug and undergoes a non-enzymatic pH-
d e p e n d e n t r e a c t i o n t o t h e mo n o e p o x y - a n d
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diepoxytransformers (Fig. 1) [7]. The products of this reaction
alkylate DNA at the N7 position of guanine [8]. The optimal
dosing regimen of high-dose TREO is still not established and
may vary between medical centers [5]. Most commonly,
TREO is administered on three subsequent days prior to the
transplant procedure (total dose of TREO 30–42 g/m2) [4, 6].
A daily dose of TREO (10–14 g/m2) is administered in a
single infusion.
Since the formation of epoxybutane derivatives from
TREO is a non-enzymatic process, it might be assumed that
measurement of the prodrug is adequate to describe the
alkylating activity [9]. Until now only one limited sampling
strategy (LSS) for estimating the exposure to TREO was pro-
posed [10]. However the underlying population pharmacoki-
netic model assumed a one-compartment linear pharmacoki-
netics, while other authors suggest that two-compartmental
model might more accurately describe changes of TREO con-
centration over time [9, 11–13]. Therefore the aim of this
study was to develop a population pharmacokinetic model
and to establish LSSs enabling accurate estimation of expo-
sure to TREO.
Materials and methods
Patients’ characteristics
The study included 15 pediatric patients, recruited in years
2007–2011 from the Department of Oncology, Hematology
and Pediatric Transplantation at the Poznan University of
Medical Sciences and the Department of Pediatric
Hematology, Oncology and Bone Marrow Transplantation at
the Wroclaw Medical University, with malignant and non-
malignant diseases. Detailed patients’ characteristics are pre-
sented in Table 1. Conditioning regimens prior to HSCT in-
cluded TREO administered as a 1 h or 2 h infusion at daily
doses of 10, 12, or 14 g/m2. The body surface area was calcu-
lated at clinical sites by means of Mosteller method [14]. The
study protocol was approved by the local Ethical Committee
at the Poznan University of Medical Sciences and is in accor-
dance with the 1964 Declaration of Helsinki and its later
amendments. Informed consent was obtained from the parents
prior to initiating the study.
Sampling protocol and determination of TREO
The samples were drawn in the first day of the therapy from all
of the patients. Two different sampling protocols were ap-
plied. From 7 patients the full blood samples were drawn at
0.5, 1, 3, 4, 6 and 8 h after the beginning of infusion, while
from the remaining 8 patients a more dense sampling was
allowed, at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 8 and 12 h after the start
of infusion. Immediately after collection 50 μl of 1 M citric
acid per 1 ml of full blood was added, to avoid ex vivo trans-
formation of TREO to its epoxides. Subsequently, the samples
were centrifuged and the obtained plasma was stored at
− 20 °C until the analysis.
Concentrations of TREO were determined by a validated
HPLC-MS/MS method. The method validation, as well as
preliminary pharmacokinetic analysis was published in details
elsewhere [12, 15]. Briefly, the applied method allowed accu-
rate determination of TREO in the plasma samples in ranges
0.2–5720 μM (56.6 ng/ml–1.59 mg/ml). The lower limit of
quantitation was 0.2 μM. The inter-day and intra-day preci-
sion and accuracy were calculated according to regulations of
the EuropeanMedicines Agency for bioanalytical method val-
idation. The precision of the method, described by the coeffi-
cient of variation was 1.8–11.5%, while method accuracy de-
scribed with the relative error was 0.02–11.8%.
Development of population pharmacokinetic model
Methods and software
The model development was performed in Monolix 2016R1
software (Lixoft SAS, Antony, France, http://lixoft.com/
Fig. 1 Metabolic activation of
treosulfan to its active mono- and
diepoxide
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products/monolix/) by means of stochastic approximation of
the standard expectation maximization (SAEM) algorithm for
non-linear mixed-effects models without approximation. The
maximum number of iterations at each stage of population
parameter estimation was automatically determined by the
algorithm (K1 = ‘auto’, K2 = ‘auto’). The quality of SAEM
algorithm convergence was inspected at each model estima-
tion step. Minimum 4 Markov chains were set at estimation.
Conditional means and standard deviations of individual phar-
macokinetic parameters were estimated with a Markov Chain
Monte Carlo method (MCMC). Improvement in the model fit
was evaluated with the likelihood ratio test. The difference in
the minimum objective function value (MOFV) of 10.8 (p < 0.
001) between nested models was considered significant. Also,
Akaike information criterion (AIC) and Bayesian Information
criterion (BIC) were calculated and models with lower values
of AIC and BIC were considered as better fitted to the ob-
served data. Calculation of MOFV was performed by
linearization in the initial stages of decision-making, while
an importance sampling method was used for the final model
selection. Visual examination of goodness-of-fit was based on
the following plots: individual (IPRED) and population pre-
dicted (PPRED) concentrations versus observed concentra-
tions, individual fits, population weighted (PWRES) and in-
dividual weighted residuals (IWRES) versus time and predict-
ed concentrations, normalized prediction distribution errors
(NPDE) versus time and predicted concentrations, histograms
and quantile-quantile plots.
Structural and error model selection
One-, two- and three-compartmental models for intravenous
infusion with first-order elimination were examined. Log-
normal distribution of pharmacokinetic parameters was as-
sumed and interindividual variability elements (IIV) were de-
scribed with an exponential model as follows (Eq. 1):
θij ¼ θ j  eηij ð1Þ
where θij is a value of j-th pharmacokinetic parameter for i-th
individual, θj is the population parameter estimate and ηij is a
random variable characterizing IIV.
Covariance between IIV elements was inspected after
building a structural model. Diagonal, full and partial covari-
ance matrices were examined and significant values were
retained in the model. Standard errors of model parameters
were calculated by means of the linearization algorithm; how-
ever, the values obtained from the final model were obtained
by stochastic approximation, which is more time consuming,
but at the same time a more precise method [16]. Also, η-
shrinkage was calculated with a following equation (Eq. 2):
Shrinkage ¼ 1− Var η^ð Þ
ω^2
ð2Þ
where η^ is the posterior estimate for individuals based on
empirical Bayes estimates and ω^ is the estimated standard
deviation for the corresponding random effect [16].
According to Savic and Karlsson [17], high shrinkage (above
20–30%) is associated with insufficient informativeness of
diagnostics based on empirical Bayes estimates, which in-
clude IPRED and IWRES.
Additive, proportional and combined (additive and propor-
tional) error models describing residual unexplained variabil-
ity (RV) were examined and following equation was applied
(Eq. 3):
Cobs ¼ Cpred  1þ ε1ð Þ þ ε2 ð3Þ
where Cobs and Cpred are observed and predicted concentra-
tions of treosulfan, ε1 is a variable associated with proportion-
al RV and ε2 defines additive portion of RV.
Table 1 Patients’ characteristics. Continuous data are presented as
means with standard deviations and minimum-maximum ranges in
brackets. Categorical data are presented as counts
Characteristic Value
Age [years] 7.8 ± 4.9 (0.4–15)
Bodyweight [kg] 26.9 ± 15.7 (7.7–52)
Body surface area [m2] 0.95 ± 0.44
(0.25–1.63)
Boys/girls [n] 12 / 3
Total daily treosulfan dose and infusion length
(n)
10 g/m2–1 h 1
12 g/m2–1 h 4
12 g/m2–2 h 4
14 g/m2–2 h 6
Creatinine clearance [ml/min] (n = 8) 123 ± 60 (71–239)
Diagnosis
Hematological malignancies
ALL 4
AML 1
CML 1
Solid tumors
NBL 2
ES 2
Non-malignant disorders
X-ALD 2
DBA 1
SCN 1
WAS 1
X-ALD adrenoleukodystrophy, ALL acute lymphoblastic leukemia, AML
acute myeloid leukemia, CML chronic myeloid leukemia, DBA
Diamond-Blackfan anemia, ES Ewing’s sarcoma, NBL neuroblastoma,
SCN severe congenital neutropenia, WASWiskott-Aldrich syndrome
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Covariate selection
Covariate model was established in a forward inclusion-
backward elimination manner. Weight and sex were examined
as potentially influential covariates. Creatinine clearance was
not considered in the covariate analysis due to lack of the data
for 7 patients out of total 15 subjects. Weight, a continuous
covariate, was standardized to adult bodyweight (70 kg).
Also, allometric scaling factor was included for clearance pa-
rameters, as suggested by Anderson and Holford [18]. Wald
test implemented in Monolix was used to evaluate the covar-
iates and p value < 0.05 was considered significant. After
including all the significant covariates, a full model was cre-
ated. Next, the covariates were eliminated from the model in a
step-by-step manner. A covariate was retained if the MOFV
increased by more than 6.67 (p < 0.01). As a result, the final
model was obtained and applied in the further analysis.
Model evaluation
Due to low number of patients included in the study, internal
methods of model validation were applied. Prediction-
corrected visual predictive check (pcVPC) was performed
for 1000 simulated observations. Contrary to a standard
VPC, pcVPC allows accurate visual presentation of the sim-
ulation results without losing power due to data stratification
[19]. In this approach observed and simulated dependent var-
iables are normalized basing on a typical population predic-
tion for the median independent variable in each bin [20]. 5th,
median and 95th percentiles of the simulated data were plotted
and compared to the corresponding percentiles of the ob-
served data. The other recommended validation procedure is
bootstrapping. Due to the fact that bootstrapping algorithms
are not implemented in Monolix, Wings for NONMEM
(WFN, version 742, http://wfn.sourceforge.net/, Nick
Holford, University of Auckland, New Zealand) with the
mlxbs script was applied. 1000 bootstrapped datasets were
used to determine medians of each estimated parameter, as
well as 5th and 95th confidence intervals (CI). Calculated
values were compared with those obtained from the final
model.
Development of a LSS
Data simulation
A simulation-based approach was applied to develop
LSSs for estimation of exposure to TREO in pediatric
patients. Firstly, the distribution of significant covariates
included in the final model was visually inspected.
Deviations from normal distribution were tested with
Shapiro-Wilk’s test. Next, a group of 100 virtual patients,
with distribution of significant covariates resembling the
original population, was simulated in the Statistica 12
software (Stat Soft Inc., Tulsa, OK, USA) by means of a
Monte -Car lo me thod . Subsequen t ly, the t ime-
concentration profiles were simulated for the virtual pa-
tients with the Simulx function of mlxR package (version
3.2.0, Inria Team for the DDMoRe project, http://simulx.
webpopix.org/) using the developed final population
model. The simulations were performed in R software
(version 3.4.0, Foundation for Statistical Computing,
Vienna, Austria). In the original study TREO was
administered in different dose levels and as a 1 h or 2 h
infusion. Therefore, for each virtual patient the
concen t r a t ions of TREO were s imula t ed a f t e r
administration of the drug as following: 12 g/m2 in 1-h
infusion, 12 g/m2 in 2-h infusion and 14 g/m2 in 2 h
infusion. As a result three groups of patients with differ-
ent types of TREO administration were created, each with
100 individuals. Following sampling times were
inspected: 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 6 h,
8 h and12 h after the beginning of the infusion. The sug-
gested sampling times as well as types of TREO admin-
istration were based on the original study protocols. All
samples in which a predicted concentration was below the
LOQ of the applied HPLC-MS/MS method (0.56 ng/ml)
were removed from further analysis. Also, the population
pharmacokinetic estimates for each subgroups were calcu-
lated and compared with the values obtained from the
final model.
Development of the regression equations for prediction
of exposure to TREO by linear regression fitting
In the first step, areas under time-concentration curves from
time 0 to infinity (AUC0 → ∞) were calculated by means of a
non-compartmental method analysis (NCA). The AUC0 → ∞
was calculated with a linear-up log-down interpolation meth-
od by means of PKNCA package (version 0.8.1, https://cran.r-
project.org/package=PKNCA) run through the R software.
Next, each of the three simulated patient groups were
randomly divided into two approximately equal subgroups.
First subgroup was a Blearning^ one, while the second
subgroup, which was labeled Bvalidation,^ was used to
evaluate the predictive performance of the strategies.
Multiple regression equations were calculated for models in
which two or three samples were required to predict
AUC0 → ∞. The calculations were performed in R software
by means of leaps package (version 3.0, https://cran.r-project.
org/package=leaps). The models were stratified upon the
adjusted coefficient of determination value (R2). Models
which assumed drawing during the infusion or sampling
at12 h after the beginning of infusions were discarded.
Finally, best two and three-point models for each type of
TREO administration were chosen for further validation.
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Bayesian estimation of exposure to TREO
The procedure was performed as described by Alsultan et al.
[21]. In the analysis, the simulated datasets described in chap-
ter 2.4.1 were used. Also, the best sampling strategies selected
by linear regression fitting were applied. First, the estimates
from the final model were fixed at the obtained values.
Second, the datasets were created in which only the sampling
times from the chosen LSSs were left. Then, the individual
pharmacokinetic parameters were calculated for each subject.
The exposure to TREO for each individual was calculated as
following (Eq. 4):
AUC0→∞ ¼ DCl ð4Þ
where D is the amount of TREO administered and Cl is total
clearance.
Evaluation of the predictive performance of LSSs
The prediction performance of LSSs was evaluated as sug-
gested by Sheiner and Beal [22]. Following parameters were
calculated for each strategy: relative prediction error (PE),
mean relative prediction error (MPE), mean absolute relative
prediction error (MAPE) and root mean squared relative pre-
diction error (RMSE). These parameters were estimated using
following equations (Eq. 5–8):
PE ¼ AUCpred
ið Þ−AUCobs ið Þ
AUCobs ið Þ
 100 ð5Þ
MPE ¼ 1
N
∑Ni
AUCpred ið Þ−AUCobs ið Þ
AUCobs ið Þ
 100 ð6Þ
MAPE ¼ 1
N
∑Ni
AUCpred ið Þ−AUCobs ið Þ




AUCobs ið Þ
 100 ð7Þ
RMSE ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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AUCpred ið Þ−AUCobs ið Þ
AUCobs ið Þ
 !2
v
u
u
t  100 ð8Þ
For each LSS, distribution symmetry and range of relative
errors was verified [23].
For the linear regression method, the best strategies were
used to predict AUC0 → ∞ of patients from the Bvalidation^
subgroup. Next, also, the LSS equations were used to predict
AUC0 → ∞ calculated from the acquired experimental data,
and the cumulative predictive performance was calculated
for the best 2- and 3-point strategies as presented above. For
the Bayesian method, the chosen strategies were used to pre-
dict AUC0 → ∞ of all patients from a given dosing subgroup
(100 patients in each).
Results
Population pharmacokinetic analysis
A total of 110 samples were obtained from the patients
and analyzed in the study. All concentrations of TREO
were above the LOQ of the HPLC-MS/MS method. A
spaghetti plot with individual time-concentration curves
is presented in Fig. 2. It was found that the experimental
data were best described by a linear two-compartmental
model with a proportional error (63.76 decrease of
MOFV), where V1 and V2 describe central and peripheral
compartment volumes, respectively, Cl is clearance and Q
is an intercompartmental clearance. Analysis of covari-
ance matrix showed that there is a significant covariance
between random variability of Cl and V1. The only covar-
iate included in the final model was patient’s weight, as
described by following equation (Eq. 9):
θij ¼ θ j  BWi70
 β
 eηij ð9Þ
where θij is a value of j-th pharmacokinetic parameter for
i-th individual, θj is the population parameter estimate,
BWi is a bodyweight of the i-th individual centered on a
typical weight of 70 kg, while β is a scaling exponent and
ηij is a random variable characterizing IIV. The values of
the exponents were first estimated and equaled 0.804 for
Cl, 0.959 for V1 and 0.925 for V2. For subsequent anal-
ysis, these values were fixed to most widely used values
of 1 for volume parameters or to 0.75 for clearance. Also,
the IIV parameters were evaluated for CL, V1 and Q only.
In the modeling process, the standard error for the esti-
mated V2 IIV was over 100%. Hence it was decided to
remove the IIV on V2 from the model. It was found that
addition of bodyweight as a covariate decreased the IIV of
CL (65.3 to 25.5%) and V1 (84.5 to 51.4%). Interestingly,
addition of bodyweight as a covariate for Q increased the
MOFV and worsened the model fit. Therefore this rela-
tionship was not included in the model. The estimates
derived from the final pharmacokinetic model are present-
ed in Table 2. Calculated η-shrinkage was 1% for Cl, 19%
for V1 and 18% for Q.
Figure 3 presents basic goodness-of-fit diagnostic plots of
the final model. Observed concentrations (OBS) plotted vs.
population predicted (PPRED) and individual predicted con-
centrations (IPRED) are scattered randomly around the line of
identity and the spline is close to the identity line (Fig. 3A).
Plots of IWRES and PWRES vs. time and PPRED are pre-
sented in Fig. 3B. For both types of residuals, the points are
randomly scattered along the y = 0 line and no significant
trends are visible. Moreover, most points fall within ±2 stan-
dard deviation with only a few points with deviations larger
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than 3. Simulation-based plots of NPDE vs. time and PPRED
(Fig. 3C) show that the 5th, median and 95th percentiles of
empirical data (solid lines) fall within the corresponding per-
centiles of the predictions (light and dark gray areas).
Performed pcVPC is presented in Fig. 4. The solid black
lines, which represent 5th, median and 95th percentile of ob-
served data fall within the areas representing respective pre-
diction intervals of the simulated data. There are only 2 points
which fall outside the plotted prediction intervals.
The results of bootstrapping are presented in Table 2.
Calculated means as well as the 5th–95th confidence intervals
are very similar to the estimates obtained with the SAEM
algorithm for the primary dataset. The largest discrepancy
was noted for the IIVof Q. However, the calculated standard
error for this particular parameter was large (52.3%) and also
small size of study group might account for the difference in
the results.
Performance of selected LSSs
Covariate analysis showed that the patient’s bodyweight is an
important cofactor. Visual inspection of the data and results of
Shapiro-Wilk’s test (p = 0.182) it was assumed that the
bodyweight was normally distributed. 100 patients with mean
Fig. 2 Spaghetti plot of
treosulfan concentrations vs. time
acquired for patients included in
the study
Table 2 Final estimates of pharmacokinetic parameters
Parameter Final model estimate (%RSE) Bootstrapped estimate (95% CI)
Typical value
Cl [l/h/70 kg] 14.7 (6.9) 14.78 (14.70–14.84)
βCl, weight 0.75 (fixed) 0.75 (fixed)
V1 [l/70 kg] 26.0 (14.0) 25.94 (25.70–26.18)
βV1, weight 1 (fixed) 1 (fixed)
Q [l/h] 2.25 (22.2) 2.63 (2.53–2.72)
V2 [l/70 kg] 9.93 (9.0) 9.89 (9.74–10.05)
βV2, weight 1 (fixed) 1 (fixed)
IIV [%]
ωCl 25.5 (19.8) 24.0 (23.6–24.3)
ωV1 51.4 (20.0) 50.8 (50.2–51.3)
ωQ 38.6 (52.3) 32.7 (31.6–33.7)
ωCl-V1 71.4 (20.7) 68.9 (67.7–70.1)
Residual proportional error 0.188 (9.01) 0.184 (0.182–0.185)
RSE relative standard error, CI confidence interval, Cl clearance, V1 central compartment volume, Q intercompartmental clearance, V2 peripheral
compartment volume, IIV interindividual variability
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body weight 26.26 ± 16.54 kg (min. 5.8 kg – max. 53.90 kg)
were simulated with a Monte-Carlo method. Next, body sur-
face area was estimated with a following equation (Eq. 10)
[24]:
BSA ¼ 4; 688 BW 0;8168−0;0154 logBWð Þ ð10Þ
where BSA is body surface area in cm2 and BW is bodyweight
in g. Obtained body surface areas were used to calculate the
exact dose of TREO (12 g/m2 or 14 g/m2) for the simulation
analysis.
For all three types of TREO administration the population
pharmacokinetic estimates were not significantly different
from the values obtained from the final model.
The best strategies and their performance for estimating
exposure to TREO, based on the simulation study, are present-
ed in Table 3. For 1-h infusion of 12 g/m2 of TREO, the best
strategies assumed sampling at 1 h and 6 h or at 1.5 h, 2 h and
6 h after the beginning of the infusion. For 2-h infusion of
12 g/m2 an accurate prediction of AUC0 → ∞ required deter-
mination of TREO concentration in samples drawn 2 h and 6 h
or 2 h, 3 h and 8 h after the beginning of infusion. While for 2-
h infusion of 14 g/m2 of the drug, sampling at 2 h and 6 h, or at
2 h, 4 h and 8 h was needed for the most accurate estimation of
exposure. The R2 is very close to the unity value and the
prediction errors are overall very small. Noteworthy, the var-
iability observed in the Bayesian prediction method is higher,
as well as the prediction errors. Also, approximately 2% of the
Fig. 3 Goodness-of-fit plots for the final pharmacokinetic model. Panel
A illustrates observed (OBS) vs. population predicted (PPRED)
treosulfan concentrations and OBS vs. individual predicted (IPRED)
treosulfan concentrations with an identity line and smooth. Panel B pre-
sents individual-weighted residuals (IWRES) vs. time and PPRED,
population-weighted residuals (PWRES) vs. time and PPRED. Panel C
presents normalized prediction distribution errors (NPDE) vs. time and
PPRED with bold lines as 5th, median and 95th percentile of observed
concentrations, light gray area as 50% interval of simulated data and dark
gray areas as 95% intervals of simulated data
Fig. 4 Prediction-corrected
visual predictive check (pcVPC)
with dots as observed treosulfan
concentrations, bold lines as 5th,
median and 95th percentile of
observed concentrations, light
gray area as 50% interval of sim-
ulated data and dark gray areas as
95% intervals of simulated data
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predictions based on this method were outside the 20% error
boundary.
The performance of the proposed LSSs was also evaluated
by comparison of observed and predicted AUC0 → ∞ in the
experimental group (Table 4). Bias in prediction of this pa-
rameter was within ±15% for all patients. Only 3-point strat-
egies in which the exposure was estimated with Bayesian
methods had RMSE slightly above 15%. Unfortunately, due
to heterogeneity in the sampling designs and lack of samples
in some time points, prediction of AUC0→ ∞was not possible
for all of the patients, while for some individuals prediction
was calculated only by means of 2-point strategies.
Discussion
There is an increasing interest in use of TREO as a basic
agent in conditioning regimens prior to hematopoietic
stem cell transplantation, both in pediatric and adult pop-
ulations [3, 25, 26]. The aim of this study was to deter-
mine a population pharmacokinetic model for TREO bas-
ing on the data acquired for pediatric population and to
develop LSSs for estimation of AUC of this drug.
According to Scheulen et al. [27], the pharmacokinetics
of TREO is linear in a wide range of doses (20–56 g/m2)
therefore it was possible to pool patients with different
dose levels and it might be assumed that the dose would
not have an impact on the estimations. It was found that
the pharmacokinetics of TREO was best described with a
linear two-compartmental model with a proportional re-
sidual error. The covariate analysis showed that
bodyweight was significantly associated with the estimat-
ed values of Cl, V1 and V2. Interestingly, visual inspec-
tion of data and analysis of MOFV did not support inclu-
sion of bodyweight as an important covariate of Q.
Although the explanation of this phenomenon remains
unknown, one of the reasons might be unique metabolic
activation of TREO. Scaling of parameters, especially al-
lometric scaling of clearance parameters, describes an in-
crease in the metabolic rate [28]. At the same time acti-
vation of TREO is a pH- and temperature-dependent pro-
cess and does not require enzymatic conversion.
Therefore the lack of relationship between Q and
bodyweight might, to some extent, reflect this pathway.
The conversion of TREO to epoxides might occur
throughout the whole body both in the central and periph-
eral compartments. However, more studies are needed,
especially the combined parent-metabolite modeling ap-
proach, to sufficiently explore this observation. The other
tested covariate, patient’s sex, was not found significant.
One explanation of these observations might be the fact
that the study group included three girls only and this
number might be insufficient to observe potentially
existing relationships between estimated parameters.
Also, some authors note that patient’s sex might be an
important factor in children older than 12 years of age
Table 3 Performance of chosen two and three-point LLSs based on linear regression fitting and Bayesian estimation for prediction of exposure to
treosulfan after different dosing regimens
Equation (if applicable) R2 PE > 20% PE < 20% MPE [%] MAPE [%] RMSE [%]
12 g/m2 in 1 h infusion
AUCpred = 0.86×C1 h + 1.93×C2 h + 7.47×C6 h – 42.2 0.9978 0 0 0.13 1.13 1.36
AUCpred = 2.78×C1.5 h + 6.62×C6 h – 45.6 0.9743 0 0 − 0.12 2.78 4.09
Bayesian estimation from C1 h, C2 h, C6 h – 0 0 − 0.95 3.55 4.39
Bayesian estimation from C1.5 h, C6 h – 0 0 − 0.36 6.58 7.86
12 g/m2 in 2 h infusion
AUCpred = 1.82×C2 h + 1.51×C3 h + 9.39×C8 h – 24.1 0.9993 0 0 0.11 0.78 0.93
AUCpred = 2.10×C2 h + 7.73×C6 h + 2.94 0.9929 0 0 − 0.29 1.40 1.67
Bayesian estimation from C2 h, C3 h, C8 h – 0 0 − 0.61 4.35 5.60
Bayesian estimation from C2 h, C6 h – 2 0 0.50 5.37 7.56
14 g/m2 in 2 h infusion
AUCpred = 2.01×C2 h + 2.15×C4 h + 7.68×C8 h – 9.07 0.9998 0 0 − 0.29 0.45 0.62
AUCpred = 2.07×C2 h + 7.57×C6 h + 42.6 0.9972 0 0 − 0.29 1.37 1.61
Bayesian estimation from C2 h, C4 h, C8 h – 1 0 − 0.92 5.13 6.68
Bayesian estimation from C2 h, C6 h – 1 0 0.24 5.97 8.12
LSS limited sampling strategy, R2 adjusted coefficient of determination, PE relative prediction error,MPE mean relative prediction error, MAPE mean
absolute relative prediction error, RMSE root mean squared relative prediction error, AUCpred predicted area under time-concentration curve, Cnh
concentration of treosulfan measured n hours after the beginning of infusion
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[29]. In the study group only four children (three boys and
one girl) could be qualified into this category and there-
fore a more thorough investigation of this potential co-
variance could not be performed. Previous studies on
pharmacokinetics of TREO indicate that up to 39% of
total dose of this drug is excreted renally [12]. As a con-
sequence, parameters which describe renal function such
as creatinine clearance might be important covariates for
Cl. However, in the present study, this factor was not
included in the analysis. First of all, data on creatinine
clearance was available for eight children (53% of total).
Several methods to overcome the problem of missing data
were considered in this analysis—exclusion of patients
with lack of information on creatinine clearance or impu-
tation with a median value [30]. Although removing indi-
viduals with missing covariate data gives relatively unbi-
ased results, the estimates are less precise. Imputation of a
median value might significantly bias the results of the
study. Noteworthy, no significant trends were observed
in the plots of neither Cl vs. creatinine clearance nor
IIVCl vs. creatinine clearance. Also, the available data
on creatinine clearance indicate that the renal function in
patients could be described as normal. Therefore, to in-
vestigate the influence of this parameter on pharmacoki-
netics of TREO a larger study group would be necessary.
The parameter estimations obtained in the present study are
similar to the results reported by other authors. In adult pop-
ulations [9, 13, 26] estimated total clearance ranged from 8.7 l/
h to 13.5 l/h, while mean steady-state volume of distribution
(Vss), which represents both central and peripheral compart-
ments, was ranging from 19.5 l to 34 l. The obtained values
are also similar to the ones presented by ten Brink et al. (Vc/
70 kg = 43.05 l, Cl/70 kg = 16.12 l/h) [10]; however, it has to
be noted that the model assumed by those authors is one-
compartmental. The IIVof calculated parameters was relative-
ly large, reaching up to 51.4%. According to the presented
goodness-of-fit plots (Fig. 3), pcVPC (Fig. 4) and bootstrap
analysis (Table 2), proposed model adequately describes
changes of TREO concentration over time.
Overall, the results are in some contrast with the results of
ten Brink et al. [10] who developed a one-compartment mod-
el. These authors note that using a two-compartmental model
did not sufficiently lower the MOFV (< 10.8 decrease in the
MOFV). However, a systematic bias is noticeable in the
conditional-weighted residuals vs. time graphs presented by
these authors. It indicates that the addition of peripheral com-
partment might had improved themodel. Therefore, the model
developed in the present study might be superior to the previ-
ous one and allows better prediction of changes in TREO
concentration over time.
The best LSSs developed on a basis of the proposed pop-
ulation pharmacokinetic model were shown to have good pre-
dictive properties (Table 3). Interestingly, the equations pro-
posed for estimation of AUC0 → ∞ on a 2-sample basis were
very similar for 2-h infusions of 12 g/m2 and 14 g/m2. This is
an understandable consequence of the assumed linearity of
TREO pharmacokinetics. Moreover, the strategies were ap-
plied to predict the AUC0 → ∞ in the experimental group and
the predictive performance was acceptable.
As administration of TREO in HSCT in pediatric popula-
tions is still a relatively new issue, because standard proce-
dures rather include busulfan, a uniform system for estimation
of exposure is yet to be evaluated. Also, the exact and detailed
protocols for monitoring of TREO have also not been pub-
lished yet, beside the work by ten Brink et al. [10]. TREO
itself is a prodrug, and its pharmacological effect is dependent
on the epoxytransformers. Since the concentrations of TREO
are much higher than the concentrations of its Bmetabolites,^
they are much easier to monitor. Therefore the monitoring
procedure based on the prodrug concentration was proposed.
To our knowledge, no studies were published which would
bind directly the efficacy and safety of TREO with its phar-
macokinetics and several authors point out the need of further
studies in this particular area [4, 5]. It might be possible that
the levels of TREO epoxides have higher predictive value for
safety, toxicity and efficacy of this treatment. However, exact
data which combine follow-up data and the epoxides concen-
trations would be required for this assessment.
Table 4 Performance of proposed LSSs for prediction of AUC0 → ∞ in the primary group of patients
Linear regression method Bayesian method
2-point strategies (n = 7) 3-point strategies (n = 5) 2-point strategies (n = 7) 3-point strategies (n = 5)
PE > 20% 0 0 0 0
PE < − 20% 0 0 0 0
MPE [%] 0.89 − 6.25 1.04 − 2.05
MAPE [%] 8.43 9.72 11.07 13.51
RMSE [%] 9.33 11.34 12.56 15.83
LSS limited sampling strategy, PE relative prediction error, MPE mean relative prediction error, MAPE mean absolute relative prediction error, RMSE
root mean squared relative prediction error
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The major limitation of the study is small sample size.
Therefore, an external validation procedure is required prior
to employing the proposed LSS in the clinical practice.
Conclusions
In conclusion, in the present study a two-compartmental pop-
ulation pharmacokinetic model of TREO was developed and
successfully used to establish 2- and 3-point LSSs for accurate
and precise estimation of TREO AUC0 → ∞.
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